Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06557239
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-12
Brief Title:
Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy for Anxiety and Depression a Pilot Study
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PAP_OXT
Brief Summary:
The main objective of this pilot study is to obtain preliminary data on the reactivity of salivary oxytocin during a single LSD intake as part of PAP treatment for anxiety disorders or depression treatment authorisations granted in advance by the Federal Officie of Public Health for compassionate use of the substance
There will be no interference with the usual clinical routine in our Service The protocol is only for taking additional saliva measurements to measure oxytocin levels on the day of treatment
Participants will be asked to give 4 saliva samples the day of their LSD treatment In addition they will fill-in self-report questionnaires which are part of the clinical routine
There will be no interference with the usual clinical routine in our Service The protocol is only for taking additional saliva measurements to measure oxytocin levels on the day of treatment
Participants will be asked to give 4 saliva samples the day of their LSD treatment In addition they will fill-in self-report questionnaires which are part of the clinical routine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None